Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Myeloid Malignancies

NCT06917105 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Myeloid Malignancies
CAR-T

Interventions

DRUG: CD33/CD123/CLL-1 CAR-T Cells

Sponsor

Tongji Hospital

Collaborators

[object Object]